Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

• Published in: Cardiology and Therapy 2024-12, Vol.13 (4), p.737-760
• Main Authors: Tse, Hung-Fat, Chang, Hung-Yu, Colquhoun, David, Kim, Jung-Sun, Poh, Kian Keong, Kostner, Karam, Hutayanon, Pisit, Cho, Meejin, Lange, Jeff, Kodiappan, Kamlanathan, Leekha, Saikiran
• Format: Article
• Language: English
• Subjects: Asia; Australia; Cardiac patients; Cardiology; Cardiovascular diseases; Care and treatment; Chart review; Cholesterol; Decision-making; Drug therapy; Health aspects; Hypercholesterolemia; Internal Medicine; Low density lipoproteins; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Observational research; Original Research; Patient compliance; Patient-reported outcome; Physician feedback; Physicians
• ISSN: 2193-8261; 2193-6544
• DOI: 10.1007/s40119-024-00384-3

Introduction Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia–Pacific clinical practice. Description of evolocumab use among adults with establis H ed A therosclerotic cardiovascu L ar diseas E or hypercholesterolemia in A S ia–Pacific region (HALES) was performed to better understand characteristics of and clinical decision-making for adults with established atherosclerotic cardiovascular disease/hypercholesterolemia after local evolocumab approval. Methods The HALES observational study, conducted at 33 sites (Hong Kong, Thailand, South Korea, Singapore, Taiwan, and Australia) comprised (1) chart review of patients who received evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), and (2) physician/patient survey and one-time data collection of patients with high cardiovascular risk initiating evolocumab or initiating/continuing non-PCSK9i lipid-lowering therapy. Patients could only enroll in (1) or (2). Results Chart review included 724 very high-risk patients initiating evolocumab from regulatory approval to 2021. From median baseline LDL-C of 3.2 mmol/L (123.7 mg/dL), patients had a median percent change in LDL-C of − 60.8% at 1–6 months. Goal achievement increased from 7.9% to 69.8% for